These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22226290)

  • 1. An analysis of dosage volume for halfway doses in the Victoza Pen.
    Kroon L
    J Diabetes Sci Technol; 2011 Nov; 5(6):1625-6. PubMed ID: 22226290
    [No Abstract]   [Full Text] [Related]  

  • 2. Accuracy of dosage volume for halfway doses in the Victoza Pen.
    King AB; Wolfe GS
    J Diabetes Sci Technol; 2011 Nov; 5(6):1623-4. PubMed ID: 22226289
    [No Abstract]   [Full Text] [Related]  

  • 3. [Basal insulin and liraglutide combined in a pen].
    Rausch R
    Med Monatsschr Pharm; 2015 Apr; 38(4):154-6. PubMed ID: 26364391
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide.
    Kapitza C; Zdravkovic M; Zijlstra E; Segel S; Heise T; Flint A
    J Clin Pharmacol; 2011 Jun; 51(6):951-5. PubMed ID: 20671294
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.
    Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ
    Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attempted suicide with liraglutide overdose did not induce hypoglycemia.
    Nakanishi R; Hirose T; Tamura Y; Fujitani Y; Watada H
    Diabetes Res Clin Pract; 2013 Jan; 99(1):e3-4. PubMed ID: 23149376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide-induced acute pancreatitis.
    Jeyaraj S; Shetty AS; Kumar CR; Nanditha A; Krishnamoorthy S; Raghavan A; Raghavan K; Ramachandran A
    J Assoc Physicians India; 2014 Jan; 62(1):64-6. PubMed ID: 25327099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.
    Courrèges JP; Vilsbøll T; Zdravkovic M; Le-Thi T; Krarup T; Schmitz O; Verhoeven R; Bugáñová I; Madsbad S
    Diabet Med; 2008 Sep; 25(9):1129-31. PubMed ID: 19183322
    [No Abstract]   [Full Text] [Related]  

  • 9. Hormone copycats.
    Gebel E
    Diabetes Forecast; 2012 Jun; 65(6):36, 38-9. PubMed ID: 22737769
    [No Abstract]   [Full Text] [Related]  

  • 10. Liraglutide in clinical practice: dosing, safety and efficacy.
    Peterson GE; Pollom RD
    Int J Clin Pract Suppl; 2010 Oct; (167):35-43. PubMed ID: 20949699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liraglutide (Victoza) for type 2 diabetes.
    Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which incretin-based therapy for type 2 diabetes?
    Scheen AJ
    Lancet; 2014 Oct; 384(9951):1325-7. PubMed ID: 25018117
    [No Abstract]   [Full Text] [Related]  

  • 13. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes.
    Yang Y; Zhang J; Ma D; Zhang M; Hu S; Shao S; Gong CX
    J Alzheimers Dis; 2013; 37(3):637-48. PubMed ID: 23948890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
    Irie S; Matsumura Y; Zdravkovic M; Jacobsen LV; Kageyama S
    Int J Clin Pharmacol Ther; 2008 Jun; 46(6):273-9. PubMed ID: 18541123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.
    Takabe M; Matsuda T; Hirota Y; Hashimoto N; Nakamura T; Sakaguchi K; Ogawa W; Seino S
    Diabetes Res Clin Pract; 2012 Dec; 98(3):e32-5. PubMed ID: 23068961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide.
    Drucker DJ; Dritselis A; Kirkpatrick P
    Nat Rev Drug Discov; 2010 Apr; 9(4):267-8. PubMed ID: 20357801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide: from clinical trials to clinical practice.
    Gough SC
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():33-40. PubMed ID: 22405267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological and clinical profiles of a human GLP-1 analogue, liraglutide (Victoza(®))].
    Sugii H; Matsumura Y; Inoue A; Horigome H; Matsuzaki K; Shimizu A
    Nihon Yakurigaku Zasshi; 2010 Oct; 136(4):233-41. PubMed ID: 20948161
    [No Abstract]   [Full Text] [Related]  

  • 19. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
    Rendell M
    Drugs Today (Barc); 2015 Mar; 51(3):185-96. PubMed ID: 25876562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
    Bode B
    Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.